3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
4
Active not recruiting
2
Withdrawn
1
Unknown
1
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Genitourinary
1
Gastrointestinal
1
Conditions
Prostatic Neoplasms
18
Neoplasms
18
Breast Neoplasms
16
Colorectal Neoplasms
12
Carcinoma, Non-Small-Cell Lung
11
Lung Neoplasms
10
Urinary Bladder Neoplasms
6
Squamous Cell Carcinoma of Head and Neck
6
Hematopoietic and Lymphatic System Neoplasm
6
Hematologic Neoplasms
6
Ovarian Neoplasms
5
Neoplasm Metastasis
5
Triple Negative Breast Neoplasms
4
Leukemia, Myeloid, Acute
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Pancreatic Neoplasms
3
Multiple Myeloma
3
Mouth Neoplasms
3
Hematopoietic and Lymphoid System Neoplasm
3
Head and Neck Neoplasms
3
Fallopian Tube Neoplasms
3
Carcinoma, Renal Cell
3
Sarcoma
2
Radiodermatitis
2
Peritoneal Neoplasms
2
Pathologic Complete Response
2
Parotid Neoplasms
2
Motor Activity
2
Melanoma
2
Malignant Solid Neoplasm
2
Interventions
Oxaliplatin
13
Bevacizumab
11
Capecitabine
10
Fluorouracil
8
Blood Specimen Collection
8
Leucovorin
7
Cetuximab
6
pembrolizumab
5
Folfox protocol
5
trifluridine tipiracil drug combination
4
dostarlimab
4
Nivolumab
4
Irinotecan
4
HMPL-013
4
Drug Therapy
4
fludarabine
3
XELOX
3
Specimen Handling
3
Laparoscopy
3
IFL protocol
3
Cyclophosphamide
3
Biopsy
3
tislelizumab
2
tipiracil
2
regorafenib
2
pertuzumab
2
envafolimab
2
encorafenib
2
cemiplimab
2
atezolizumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Colonic Neoplasms
×
Standard of Care
×
Clear all
NCT06563388
2026-02-04
ID-COMET
Roswell Park Cancer Institute
Phase 3
Recruiting
800 enrolled